ClinicalTrials.gg
CompletedNCT01276509OPERAUpdated Jun 3, 2021Results posted

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

A Phase 2 interventional study of PF-00547659 SC injection and PF-00547659 SC injection in Crohn's Disease, sponsored by Shire. Completed at 137 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.

Enrollment
14th of 51
265 · median 100
Started
2011
with 1 other
Phase 2
13 of 86
3 open now
Registered
9th of 86
by date

Among the 86 studies in Crohn Disease by Takeda, this one is the 14th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2011, is one of 13 in phase 2, and was the 9th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Crohn Disease by Takeda, or all of them as a file.
02

Study summary

Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug). Disease activity will be measured every two weeks.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's disease Safety Efficacy Pharmacokinetics Pharmacodynamics Crohn's Disease Activity Index (CDAI)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have failed or are intolerant to anti-TNFs and/or (AZA, 6-MP, and/or MTX).
  • hsCRP greater than 3mg/L
  • Ulcerations demonstrated by colonoscopy performed during screening or 8 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding
  • Short bowel syndrome due to multiple small bowel resections
  • Presence of a stoma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • Placebo comparator
    Placebo-SC Injection

    Placebo delivered SC, 3 doses separated by 4 weeks.

    Drug: PF-00547659 SC injection

  • Experimental
    Drug Dose level 1- SC injection

    Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.

    Drug: PF-00547659 SC injection

  • Experimental
    Drug Dose level 2-SC injection

    Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.

    Drug: PF-00547659 SC injection

  • Experimental
    Drug Dose level 3- SC injection

    Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.

    Drug: PF-00547659 SC injection

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate

    Crohn's Disease Activity Index (CDAI) is a number which consists of information collected from a 7-day diary from the participants regarding symptoms. Remission is considered a score of 150 or less. Active disease is considered 200 or greater. A response to therapy is considered a decline in CDAI score of 70-points from baseline. CDAI response rate at week 8 and week 12 was measured between the investigational product group and the placebo group.

    Time frame: Week 8 and week 12

Secondary outcomes

  1. Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo

    Number of participants with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported.

    Time frame: Week 0-12

  2. Number of Adverse Events (AEs) - PF-00547659 Dose Levels Versus Placebo

    Number of adverse events (all causalities and treatment related) was reported between the investigational product groups and the placebo group.

    Time frame: Week 0-12

  3. Percentage of Participants With a Crohn's Disease Activity Index (CDAI) Remission

    Percentage of participants with a CDAI remission (defined as a CDAI reduction to \<150 points).

    Time frame: Weeks 8 and week 12

  4. Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time

    Percentage of participants with Crohn's Disease Activity Index (CDAI)-70 response were reported.

    Time frame: Week 2, 4, 6, 8, 10 and 12

  5. Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer

    Percentage of participants with Crohn's Disease Activity Index (CDAI)-100 response were reported.

    Time frame: Week 2, 4, 6, 8, 10 and 12

  6. Immunogenicity Assessment of Anti-drug Antibodies (ADAs)

    Confirmed cumulative incidence of anti-drug antibodies development to PF-00547659

    Time frame: Day 1, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36

  7. The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)

    The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time.

    Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

  8. The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)

    The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks)

    Time frame: Day 1, 14, and 28

  9. The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)

    The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration.

    Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

  10. The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)

    The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax.

    Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

  11. The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)

    The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life.

    Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

  12. The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)

    The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance.

    Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

07

Results

Posted Apr 13, 2017

Participant flow

Participant flow — Overall Study
MilestonePF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Started66656863
Completed53536358
Not completed131255
Withdrew: Adverse event9843
Withdrew: Lack of efficacy2112
Withdrew: Pregnancy1000
Withdrew: Withdrawal by subject1200
Withdrew: Other0100

Outcome measures

PrimaryPercentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate

Crohn's Disease Activity Index (CDAI) is a number which consists of information collected from a 7-day diary from the participants regarding symptoms. Remission is considered a score of 150 or less. Active disease is considered 200 or greater. A response to therapy is considered a decline in CDAI score of 70-points from baseline. CDAI response rate at week 8 and week 12 was measured between the investigational product group and the placebo group.

Time frame:
Week 8 and week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate
Percentage of ParticipantsPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Week 8 (n =50, 55, 62, 56)52.760.162.747.7
Week 12 (n = 51, 49, 61, 54)62.064.757.558.6
Statistical analysis
  • PF-00547659 22.5 mg vs Placebo · Mixed Models Analysis · p = 0.3393 · Difference in percentage: 0.050 · 90% CI -0.149 to 0.249
  • PF-00547659 75 mg vs Placebo · Mixed Models Analysis · p = 0.1433 · Difference in percentage: 0.124 · 90% CI -0.068 to 0.316
  • PF-00547659 225 mg vs Placebo · Mixed Models Analysis · p = 0.0922 · Difference in percentage: 0.150 · 90% CI -0.036 to 0.335
  • PF-00547659 22.5 mg vs Placebo · Mixed Models Analysis · p = 0.3864 · Difference in percentage: 0.034 · 90% CI -0.158 to 0.225
  • PF-00547659 75 mg vs Placebo · Mixed Models Analysis · p = 0.3005 · Difference in percentage: 0.061 · 90% CI -0.131 to 0.253
  • PF-00547659 225 mg vs Placebo · Mixed Models Analysis · p = 0.5385 · Difference in percentage: -0.011 · 90% CI -0.198 to 0.176
SecondarySafety and Tolerability of PF-00547659 Dose Levels Versus Placebo

Number of participants with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported.

Time frame:
Week 0-12
Reported as:
Number · Number of participants
Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo
Number of participantsPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Participants with AEs (all causalities)57515454
Participants with AEs (treatment related)20242922
Withdrawal due to AEs (all causalities)9843
Withdrawal due to AEs (treatment related)5201
Participants with SAEs (all causalities)119115
Participants with SAEs (treatment related)4422
SecondaryNumber of Adverse Events (AEs) - PF-00547659 Dose Levels Versus Placebo

Number of adverse events (all causalities and treatment related) was reported between the investigational product groups and the placebo group.

Time frame:
Week 0-12
Reported as:
Number · events
Number of Adverse Events (AEs) - PF-00547659 Dose Levels Versus Placebo
eventsPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Number of AEs (all causalities)175192192141
Number of AEs (treatment related)40556440
SecondaryPercentage of Participants With a Crohn's Disease Activity Index (CDAI) Remission

Percentage of participants with a CDAI remission (defined as a CDAI reduction to \<150 points).

Time frame:
Weeks 8 and week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Crohn's Disease Activity Index (CDAI) Remission
Percentage of ParticipantsPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Week 8 (n = 50, 56, 62, 57)29.123.826.916.7
Week 12 (n= 51, 49, 61, 55)26.828.529.623.0
Statistical analysis
  • PF-00547659 22.5 mg vs Placebo · Mixed Models Analysis · p = 0.1234 · Difference in percentage: 0.124 · 90% CI -0.052 to 0.299
  • PF-00547659 75 mg vs Placebo · Mixed Models Analysis · p = 0.2378 · Difference in percentage: 0.071 · 90% CI -0.092 to 0.234
  • PF-00547659 225 mg vs Placebo · Mixed Models Analysis · p = 0.1529 · Difference in percentage: 0.102 · 90% CI -0.062 to 0.266
  • PF-00547659 22.5 mg vs Placebo · Mixed Models Analysis · p = 0.3661 · Difference in percentage: 0.038 · 90% CI -0.146 to 0.222
  • PF-00547659 75 mg vs Placebo · Mixed Models Analysis · p = 0.3169 · Difference in percentage: 0.055 · 90% CI -0.136 to 0.246
  • PF-00547659 225 mg vs Placebo · Mixed Models Analysis · p = 0.2755 · Difference in percentage: 0.066 · 90% CI -0.116 to 0.248
SecondaryCrohn's Disease Activity Index (CDAI)-70 Response Rates Over Time

Percentage of participants with Crohn's Disease Activity Index (CDAI)-70 response were reported.

Time frame:
Week 2, 4, 6, 8, 10 and 12
Reported as:
Number · Percentage of Participants
Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time
Percentage of ParticipantsPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Week 2 (n = 64, 60, 63, 60)35.1 (22.8 to 49.6)22.4 (12.9 to 36.0)33.8 (21.6 to 48.5)35.5 (22.9 to 50.5)
Week 4 (n = 58, 60, 65, 58)38.0 (24.9 to 53.2)39.5 (26.3 to 54.4)36.2 (23.7 to 51.0)38.3 (25.1 to 53.5)
Week 6 (n =56, 54, 64, 58)45.3 (31.1 to 60.3)53.4 (38.2 to 67.9)47.5 (33.3 to 62.1)48.0 (33.5 to 62.9)
Week 8 (n =50, 55, 62, 56)52.7 (37.2 to 67.7)60.1 (44.9 to 73.6)62.7 (47.9 to 75.4)47.7 (33.1 to 62.7)
Week 10 (n =50, 48, 60, 52)67.4 (52.0 to 79.7)58.2 (42.3 to 72.6)61.6 (46.8 to 74.6)53.0 (37.6 to 67.8)
Week 12 (n = 51, 49, 61, 54)62.0 (46.5 to 75.3)64.7 (48.9 to 77.8)57.5 (42.6 to 71.2)58.6 (43.3 to 72.4)
SecondaryCrohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer

Percentage of participants with Crohn's Disease Activity Index (CDAI)-100 response were reported.

Time frame:
Week 2, 4, 6, 8, 10 and 12
Reported as:
Number · Percentage of Participants
Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer
Percentage of ParticipantsPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Week 2 (n = 64, 60, 63, 60)19.3 (10.6 to 32.6)18.4 (9.9 to 31.7)20.0 (11.0 to 33.6)18.5 (9.9 to 31.9)
Week 4 (n = 58, 60 ,65, 58)29.2 (17.5 to 44.6)32.3 (20.0 to 47.5)28.2 (17.0 to 43.0)29.5 (17.7 to 44.9)
Week 6 (n =56, 54, 64, 58)40.6 (26.6 to 56.4)42.6 (28.2 to 58.5)40.4 (26.8 to 55.8)39.3 (25.5 to 55.0)
Week 8 (n = 50, 55, 62, 56)50.5 (34.8 to 66.2)48.3 (33.3 to 63.7)57.0 (41.8 to 71.0)41.4 (27.2 to 57.3)
Week 10 (n = 50, 48, 62, 52)53.2 (37.3 to 68.5)47.4 (31.8 to 63.5)50.9 (35.9 to 65.7)43.6 (28.7 to 59.7)
Week 12 (n = 51, 49, 61, 54)56.0 (40.1 to 70.7)47.7 (32.2 to 63.7)53.8 (38.7 to 68.4)44.4 (29.6 to 60.2)
SecondaryImmunogenicity Assessment of Anti-drug Antibodies (ADAs)

Confirmed cumulative incidence of anti-drug antibodies development to PF-00547659

Time frame:
Day 1, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36
Reported as:
Number · events
Immunogenicity Assessment of Anti-drug Antibodies (ADAs)
eventsPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mg
Day 1 (n =46, 52, 53)351
Week 4 (n = 55, 52, 55)242
Week 8 (n = 44, 47, 56)111
Week 12 (n = 47, 51, 51)351
Week 20 (n = 4, 3, 1)000
Week 28 (n = 8, 1, 1)100
Week 36 (n = 6, 2, 1)000
SecondaryThe Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time.

Time frame:
Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
Reported as:
Geometric mean · µg•hr/mL
The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)
µg•hr/mLPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mg
The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)615300 ± 634464000 ± 2813760000 ± 49
SecondaryThe Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks)

Time frame:
Day 1, 14, and 28
Reported as:
Geometric mean · µg•hr/mL
The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)
µg•hr/mLPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mg
The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)549500 ± 534214000 ± 3110850000 ± 45
SecondaryThe Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration.

Time frame:
Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
Reported as:
Geometric mean · µg/mL
The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)
µg/mLPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mg
The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)1756 ± 4510800 ± 2224100 ± 47
SecondaryThe Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax.

Time frame:
Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
Reported as:
Median · Hours
The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)
HoursPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mg
The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)140 ± 45143 ± 22165 ± 47
SecondaryThe Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life.

Time frame:
Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
Reported as:
Mean · Day
The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)
DayPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mg
The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)4.977 ± 2.84358.770 ± 2.357112.22 ± 3.8306
SecondaryThe Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance.

Time frame:
Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
Reported as:
Geometric mean · mL/hr
The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)
mL/hrPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mg
The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)36.54 ± 6316.79 ± 2816.38 ± 49

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-00547659 22.5 mg—12/66 (18.2%)36/66 (54.5%)
PF-00547659 75 mg—11/65 (16.9%)32/65 (49.2%)
PF-00547659 225 mg—11/68 (16.2%)42/68 (61.8%)
Placebo—6/63 (9.5%)35/63 (55.6%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
Crohn's diseaseGastrointestinal disorders5/666/654/684/63
AppendicitisInfections and infestations2/660/650/680/63
Small intestinal obstructionGastrointestinal disorders0/661/652/680/63
Rectal stenosisGastrointestinal disorders0/660/650/681/63
PyrexiaGeneral disorders0/661/651/681/63
Anal abscessInfections and infestations0/661/651/681/63
Fistula of small intestineGastrointestinal disorders0/661/650/680/63
Intestinal obstructionGastrointestinal disorders0/661/650/680/63
SepsisInfections and infestations0/661/650/680/63
Staphylococcal infectionInfections and infestations0/661/650/680/63
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlacebo
PyrexiaGeneral disorders5/666/658/687/63
HeadacheNervous system disorders6/663/658/686/63
NauseaGastrointestinal disorders7/664/655/687/63
Crohn's diseaseGastrointestinal disorders5/667/651/685/63
Abdominal painGastrointestinal disorders7/661/654/683/63
ArthralgiaMusculoskeletal and connective tissue disorders5/666/655/683/63
NasopharyngitisInfections and infestations3/664/655/685/63
Urinary tract infectionInfections and infestations2/661/653/685/63
FatigueGeneral disorders5/664/652/683/63
Oedema peripheralGeneral disorders0/661/655/680/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)PF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlaceboTotal
Mean37.3 ± 13.034.4 ± 10.735.9 ± 11.034.4 ± 11.135.5 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)PF-00547659 22.5 mgPF-00547659 75 mgPF-00547659 225 mgPlaceboTotal
Female48354330156
Male18302533106
08

Study locations

137 sites
  • Clopton Clinic
    Jonesboro, Arkansas 72401, United States
  • Gastroenterology Specialists of Arkansas
    Jonesboro, Arkansas 72401, United States
  • Little Rock Diagnostic Clinic, P.A.
    Little Rock, Arkansas 72205, United States
  • UCSD Medical Center-Thornton Hospital
    La Jolla, California 92037, United States
  • Community Clinical Trials
    Orange, California 92868, United States
  • Gastro Diagnostics
    Orange, California 92868, United States
  • Inland Gastroenterology Medical Associates, Inc.
    Redlands, California 92374, United States
  • BioMark Research Inc.
    Whittier, California 90603, United States
  • Clinical Research of the Rockies
    Lafayette, Colorado 80026, United States
  • Rocky Mountain Gastroenterology Associates
    Thornton, Colorado 80229, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Shands Endoscopy Center
    Gainesville, Florida 32608, United States
  • Shands Hospital at the University of Florida
    Gainesville, Florida 32610, United States
  • Shands Medical Plaza
    Gainesville, Florida 32610, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Florida Center for Gastroenterology
    Largo, Florida 33777, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • University of Miami Hospital and Clinic
    Miami, Florida 33136, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • University of Miami
    Miami, Florida FL 33136, United States
  • Cirtus Ambulartory Surgery Center
    Orlando, Florida 32806, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Heartland Medical Research (Administrative Only)
    Clive, Iowa 50325, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • Iowa Endoscopy Center (Colonoscopy Only)
    Clive, Iowa 50325, United States
  • Metropolitan Gastroenterology Group, PC - Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Massachusetts Worcester
    Worcester, Massachusetts 01655, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Surgical Centers of Michigan
    Troy, Michigan 48098, United States
  • Minneapolis Heart Institute, West Health Campus
    Minneapolis, Minnesota 55404, United States
  • Noran Neurology Clinic
    Minneapolis, Minnesota 55407, United States
  • Consulting Radiology (Xray testing only)
    Plymouth, Minnesota 55446, United States
  • Minnesota Gastroenterology, P.A.
    Plymouth, Minnesota 55446, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Surgery Center of Columbia
    Columbia, Missouri 65201, United States
  • Audrain Medical Center
    Mexico, Missouri 65265, United States
  • Center for Digestive and Liver Diseases, Inc.
    Mexico, Missouri 65265, United States
  • Barnes-Jewish Hospital - Investigational Drug Services
    Saint Louis, Missouri 63110, United States
  • Center for Advanced Medicine
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Life Medi-Research And Management
    Brooklyn, New York 11206, United States
  • New York Hospital Queens
    Flushing, New York 11355, United States
  • Long Island Clinical Research Associates, LLP
    Great Neck, New York 11021, United States
  • Nassau Gastroenterology Associates Office Based Surgery
    Great Neck, New York 11021, United States
  • Nassau Gastroenterology Associates, P.C.
    Great Neck, New York 11021, United States
  • North Shore Primary Care, P.C.
    Great Neck, New York 11021, United States
  • Beth Israel Medical Center - Phillip Ambulatory Care Center
    New York, New York 10003, United States
  • East side Endoscopy, LLC (for colonscopy testing only)
    New York, New York 10010, United States
  • Lenox Hill Endoscopy Center
    New York, New York 10075, United States
  • Premier Medical Group of the Hudson Valley
    Poughkeepsie, New York 12601, United States
  • CTRC Hospital - UNC Memorial Hospital
    Chapel Hill, North Carolina 27514, United States
  • North Carolina Memorial Hospital Endoscopy Center
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals Department of Pharmacy
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals Endoscopy
    Chapel Hill, North Carolina 27517, United States
  • Hillsborough Campus
    Hillsborough, North Carolina 27278, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • The Offices of Dr. Vincent Armenio, M.D.
    East Providence, Rhode Island 02914, United States
  • Pharma Resource
    East Providence, Rhode Island 02915, United States
  • Bayside Endoscopy Center
    Providence, Rhode Island 02905, United States
  • Nashville Medical Research Institute
    Nashville, Tennessee 37205, United States
  • Pasadena Gastroenterology Associates, P.A. dba Digestive Health Center
    Pasadena, Texas 77505, United States
  • University of Utah HSC
    Salt Lake City, Utah 84132, United States
  • Charlottesville Gastroenterology Associates
    Charlottesville, Virginia 22902, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Allegiance Research Specialists
    Wauwatosa, Wisconsin 53226, United States
  • GI Associates
    Wauwatosa, Wisconsin 53226, United States
  • AKH Wien Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • UZ Gasthuisberg
    Leuven, B-3000, Belgium
  • Centre Hospitalier Universitaire de Liege
    Liege, 4000, Belgium
  • Centre Hospitalier Universitaire de Liège - Labo Biologie Clinique
    Liege, 4000, Belgium
  • Centre Hospitalier de Mouscron
    Mouscron, 7700, Belgium
  • 4-MHAT
    Sofia, 1000, Bulgaria
  • MBAL Sofiamed OOD,Otdelenie po gastroenterologia
    Sofia, 1979, Bulgaria
  • Vancouver Coastal Health - Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Vancouver Coastal Health - Vancouver Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Oshawa Clinic
    Oshawa, Ontario L1H 1B9, Canada
  • Toronto Digestive Disease Associates Inc.
    Vaughan, Ontario L4L 4Y7, Canada
  • CHU Amiens Hopital Nord Service d'Hepato-Gastroenterologie
    Amiens Cedex 01, 80054, France
  • Hopital Saint-Andre
    Bordeaux cedex, 33075, France
  • Hopital Beaujon- Essais cliniques
    Clichy Cedex, 92110, France
  • Hopital de l'Archet 2 - CHU de Nice
    NICE Cedex 3, 06202, France
  • Hopital Cochin-Essais Cliniques
    Paris, 75014, France
  • Hopital Charles Nicolle
    Rouen Cedex 1, 76031, France
  • Hopital Nord
    St Priest En Jarez, 42270, France
  • Hopital Rangueil
    Toulouse cedex 09, 31059, France
  • Charite - Campus Berlin Mitte Medizinische Klinik
    Berlin, 10117, Germany
  • Krankenhaus Martha-Maria Halle-Doelau gGmbH
    Halle, 06120, Germany
  • Universitaetsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Universitaetsfrauenklinikum Schleswig-Holstein Medizinische Klinik I, Gastroenterologie/Hepatologie
    Luebeck, 23538, Germany
  • Gastroenterologische Gemeinschaftspraxis Minden
    Minden, 32423, Germany
  • Universitaetsklinikum Regensburg
    Regensburg, 93042, Germany
  • Robert-Bosch-Krankenhaus
    Stuttgart, 70376, Germany
  • Universitaetklinikum Ulm
    Ulm, 89081, Germany
  • National Hospital Organization Hirosaki National Hospital
    Hirosaki, Aomori 036-8545, Japan
  • National Hospital Organization Takasaki General Medical Center
    Takasaki, Gunma 370-0829, Japan
  • Jikei University Hospital
    Minato-ku, Tokyo 105-8471, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan

Showing the first 100 of 137 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Saruta M, Park DI, Kim YH, Yang SK, Jang BI, Cheon JH, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick KJ, Cataldi F, Watanabe M, Hibi T. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. Intest Res. 2020 Jan;18(1):45-55. doi: 10.5217/ir.2019.00039. Epub 2020 Jan 30. PubMed 32013314 ↗
  • Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hebuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2018 Oct;67(10):1824-1835. doi: 10.1136/gutjnl-2016-313457. Epub 2017 Oct 5. PubMed 28982740 ↗
  • Hassan-Zahraee M, Banerjee A, Cheng JB, Zhang W, Ahmad A, Page K, von Schack D, Zhang B, Martin SW, Nayak S, Reddy P, Xi L, Neubert H, Fernandez Ocana M, Gorelick K, Clare R, Vincent M, Cataldi F, Hung K. Anti-MAdCAM Antibody Increases ss7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease. J Crohns Colitis. 2018 Jan 5;12(1):77-86. doi: 10.1093/ecco-jcc/jjx121. PubMed 28961803 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in Feb 2014, 34 months.

Results were first posted in Apr 2017, 3 years 2 months after primary completion. A results delay was requested in Feb 2015.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 34 months is close to that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2011
First posted
Jan 13, 2011
StartActual
Apr 6, 2011
Primary completionActual
Feb 7, 2014
CompletionActual
Oct 9, 2015
Results delay requested
Feb 8, 2015
Results first posted
Apr 13, 2017
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01276509
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 13, 2011
Start date
Apr 6, 2011
Primary completion
Feb 7, 2014
Completion
Oct 9, 2015
Results posted
Apr 13, 2017
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontamalimab

Start the discussion